Novel oral anticoagulant use in adults with congenital heart disease : a single-center experience report
Samarai, Daniel LU
; Isma, Nazim
LU
; Lindstedt, Sandra
LU
and Hlebowicz, Joanna
LU
(2023)
In Egyptian Heart Journal
75(1).
- Abstract
Background: Adults with congenital heart disease (ACHD) are a group with an increased risk of thromboembolic complications and arrhythmias. Vitamin K antagonists are the most commonly used thromboprophylaxis therapy in this population. Studies on the efficacy and safety of novel oral anticoagulants (NOAC) are scare in ACHD. A retrospective study on ACHD patients on NOAC treatment registered in the National Quality Registry for Congenital Heart Disease, SWEDCON, and National Quality Registry for Atrial fibrillation and Anticoagulation, AuriculA, from Southern Sweden. Results: Thirty patients who had been taking NOAC treatment for a minimum of 3 months were included. Their median age was 55 years (SD 17 years) and 57% were male. Median... (More)
Background: Adults with congenital heart disease (ACHD) are a group with an increased risk of thromboembolic complications and arrhythmias. Vitamin K antagonists are the most commonly used thromboprophylaxis therapy in this population. Studies on the efficacy and safety of novel oral anticoagulants (NOAC) are scare in ACHD. A retrospective study on ACHD patients on NOAC treatment registered in the National Quality Registry for Congenital Heart Disease, SWEDCON, and National Quality Registry for Atrial fibrillation and Anticoagulation, AuriculA, from Southern Sweden. Results: Thirty patients who had been taking NOAC treatment for a minimum of 3 months were included. Their median age was 55 years (SD 17 years) and 57% were male. Median follow-up was 17 months (IQR: 10–41). Eliquis was the most used NOAC (47%). Median CHA2DS2-VASc score was 2 (IQR: 0–3) and HAS-BLED was 1 (IQR: 0–2). Complex ACHD was prevalent in 27% of the patients. No thromboembolic events were recorded; however, one major bleeding, unspecified, was reported during the total cumulative patient follow-up time of 64 years. Conclusions: The results of our study, although limited in size, suggest that NOAC appear safe and effective in ACHD patients. Further and larger studies on NOAC in ACHD patients are warranted.
(Less)
- author
- Samarai, Daniel
LU
; Isma, Nazim
LU
; Lindstedt, Sandra
LU
and Hlebowicz, Joanna
LU
- organization
-
- Cardiology
- StemTherapy: National Initiative on Stem Cells for Regenerative Therapy
- Clinical and experimental lung transplantation (research group)
- Thoracic Surgery
- DCD transplantation of lungs (research group)
- NPWT technology (research group)
- WCMM-Wallenberg Centre for Molecular Medicine
- Cardiovascular Research - Immunity and Atherosclerosis (research group)
- publishing date
- 2023-12
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Atrial fibrillation, Congenital heart disease, Novel oral anticoagulants
- in
- Egyptian Heart Journal
- volume
- 75
- issue
- 1
- article number
- 3
- publisher
- Springer Open
- external identifiers
-
- scopus:85146647314
- pmid:36624331
- ISSN
- 1110-2608
- DOI
- 10.1186/s43044-022-00326-1
- language
- English
- LU publication?
- yes
- id
- 2d1ed68a-b0ea-4fea-bb82-62a1858f96c5
- date added to LUP
- 2023-02-09 15:30:30
- date last changed
- 2024-06-25 15:20:02
@article{2d1ed68a-b0ea-4fea-bb82-62a1858f96c5,
abstract = {{<p>Background: Adults with congenital heart disease (ACHD) are a group with an increased risk of thromboembolic complications and arrhythmias. Vitamin K antagonists are the most commonly used thromboprophylaxis therapy in this population. Studies on the efficacy and safety of novel oral anticoagulants (NOAC) are scare in ACHD. A retrospective study on ACHD patients on NOAC treatment registered in the National Quality Registry for Congenital Heart Disease, SWEDCON, and National Quality Registry for Atrial fibrillation and Anticoagulation, AuriculA, from Southern Sweden. Results: Thirty patients who had been taking NOAC treatment for a minimum of 3 months were included. Their median age was 55 years (SD 17 years) and 57% were male. Median follow-up was 17 months (IQR: 10–41). Eliquis was the most used NOAC (47%). Median CHA<sub>2</sub>DS<sub>2</sub>-VASc score was 2 (IQR: 0–3) and HAS-BLED was 1 (IQR: 0–2). Complex ACHD was prevalent in 27% of the patients. No thromboembolic events were recorded; however, one major bleeding, unspecified, was reported during the total cumulative patient follow-up time of 64 years. Conclusions: The results of our study, although limited in size, suggest that NOAC appear safe and effective in ACHD patients. Further and larger studies on NOAC in ACHD patients are warranted.</p>}},
author = {{Samarai, Daniel and Isma, Nazim and Lindstedt, Sandra and Hlebowicz, Joanna}},
issn = {{1110-2608}},
keywords = {{Atrial fibrillation; Congenital heart disease; Novel oral anticoagulants}},
language = {{eng}},
number = {{1}},
publisher = {{Springer Open}},
series = {{Egyptian Heart Journal}},
title = {{Novel oral anticoagulant use in adults with congenital heart disease : a single-center experience report}},
url = {{http://dx.doi.org/10.1186/s43044-022-00326-1}},
doi = {{10.1186/s43044-022-00326-1}},
volume = {{75}},
year = {{2023}},
}